Picture of Foghorn Therapeutics. logo

FHTX Foghorn Therapeutics. Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual cashflow statement for Foghorn Therapeutics., fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUS10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-51.1-68.8-101-109-98.4
Depreciation
Non-Cash Items2.97.4814.417.618.7
Unusual Items
Other Non-Cash Items
Changes in Working Capital1.228.733.4282-41.9
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-46.3-31.3-50.3194-118
Capital Expenditures-0.968-16.2-3.31-1.21-1.22
Purchase of Fixed Assets
Other Investing Cash Flow Items0.004-92.739.5-243146
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-0.964-10936.2-244144
Financing Cash Flow Items42.20
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities2421722.41.761.78
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-23.377.38.34-48.928.1